05/07/2026 06:00
Apis Partners Announces Final Close of $1.23 Billion Fund III, Double its Predecessor

Apis Partners Group (UK) Limited (“Apis”), a private equity firm investing in tech-enabled businesses in financial infrastructure and services, today announced the final close of Apis Global Growth Fund III and Apis Growth Markets Fund III (the “Funds” or “Fund III”), with combined commitments of $1.23 billion excluding co-investments, more than double its predecessor, Apis Growth Fund II, at $563 million. The Funds closed 23% above target. Reflecting the strong performance of previous funds,...

05/14/2026 05:28
Kioxia Unveils High Performance KIOXIA XG10 Series SSDs for PC OEMs

Kioxia Corporation today announced the KIOXIA XG10 Series solid state drives (SSDs), its latest high-performance client storage solution engineered for PC OEMs. Targeting the performance segment, the new KIOXIA XG10 Series leverages PCIe® 5.0 technology to significantly elevate speed and responsiveness across data-intensive client applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513852514/en/KIOXIA XG10 Series Client ...

Breach-Valdez Journalism Prize in Mexico: A Look Back at the Migrant Plight

Two investigations into the plight of migrants won the support of the jury members—including AFP—for this award, which honours the memory of two Mexican journalists murdered in 2017.

Two investigations into the plight of migrants won the support of the jury members—including AFP—for this award, which honours the memory of two Mexican journalists murdered in 2017.
04/29/2026 09:30
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the o...

05/07/2026 07:00
LMR Naturals to Showcase Leadership in Natural Ingredients at SIMPPAR, the International Exhibition of Raw Materials for Perfumery

LMR Naturals by IFF — a global leader in natural ingredients for perfumery, cosmetics and flavors — will debut its latest innovations at the International Exhibition of Raw Materials for Perfumery (SIMPPAR), May 26–27 in Grasse. During the industry event, IFF will unveil new additions to its LMR Hearts collection, highlighting its naturals expertise and pioneering science. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506065669/...

05/07/2026 07:00
Criteo Selects Navan to Modernize Global Travel Management

Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that it has been selected by Criteo, the global commerce intelligence platform, to modernize its global travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507251188/en/Global commerce intelligence platform delivers high employee satisfaction with Navan Criteo set out to provide its global workforce with an easy-to-use tra...

04/29/2026 10:00
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has a...

Israël - Hamas: steady under fire

By Phil Chetwynd, AFP Global News Director

 

The Israel-Hamas war is one of the most complex and divisive stories AFP has covered. It touches historical fault lines that are generating visceral emotions in our societies, and in our newsrooms.